Great to have an opportunity to speak with Celia Oreja-Guevara (University Hospital San Carlos and University Complutense, Madrid, Spain) around the highlights of her presentation entitled: Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study (ClinicalTrials.gov Identifier: NCT01892345).
Questions 1. What were the aims of the PREVENT study? (0:05)
2. What were the baseline regional differences in patient characteristics and use of immunosuppressive therapies? (0:45)
3. What were the outcomes across different regions? (2:50)
4. What is the broader significance of these findings? (4:24)
Speaker disclosure: Celia Oreja-Guevara reports that research funding for the study discussed in this video interview was provided by Alexion Pharmaceuticals.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
